FY2018 EPS Estimates for Clovis Oncology (CLVS) Decreased by Gabelli
Clovis Oncology (NASDAQ:CLVS) – Research analysts at Gabelli lowered their FY2018 earnings per share (EPS) estimates for shares of Clovis Oncology in a note issued to investors on Monday, November 19th. Gabelli analyst J. He now expects that the biopharmaceutical company will earn ($6.50) per share for the year, down from their previous forecast of ($6.30). Gabelli also issued estimates for Clovis Oncology’s FY2019 earnings at ($5.05) EPS, FY2020 earnings at ($3.95) EPS, FY2021 earnings at ($2.95) EPS and FY2022 earnings at ($2.60) EPS.
Several other brokerages have also commented on CLVS. ValuEngine upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 2nd. Cann began coverage on shares of Clovis Oncology in a research note on Wednesday, August 8th. They issued a “hold” rating on the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Clovis Oncology in a research report on Tuesday, October 2nd. Leerink Swann began coverage on shares of Clovis Oncology in a research report on Monday, September 24th. They set a “market perform” rating and a $30.00 target price on the stock. Finally, Guggenheim began coverage on shares of Clovis Oncology in a research report on Monday, September 17th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company’s stock. Clovis Oncology presently has an average rating of “Hold” and an average target price of $56.32.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.11). The company had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $30.11 million. Clovis Oncology had a negative net margin of 390.65% and a negative return on equity of 108.92%. The business’s revenue for the quarter was up 35.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.24) earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in CLVS. LPL Financial LLC lifted its holdings in shares of Clovis Oncology by 66.6% during the first quarter. LPL Financial LLC now owns 5,461 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 2,184 shares during the period. Bank of Montreal Can lifted its holdings in shares of Clovis Oncology by 2,420.9% during the second quarter. Bank of Montreal Can now owns 15,831 shares of the biopharmaceutical company’s stock worth $720,000 after purchasing an additional 15,203 shares during the period. Amalgamated Bank lifted its holdings in shares of Clovis Oncology by 23.9% during the second quarter. Amalgamated Bank now owns 7,283 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 1,406 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in shares of Clovis Oncology by 3.8% during the second quarter. State of New Jersey Common Pension Fund D now owns 270,000 shares of the biopharmaceutical company’s stock worth $12,277,000 after purchasing an additional 10,000 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Clovis Oncology by 39.1% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 49,849 shares of the biopharmaceutical company’s stock worth $2,267,000 after purchasing an additional 14,025 shares during the period.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Featured Story: What is a stock split?
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.